Temsirolimus (Torisel) — CPB 0873 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0873 governing temsirolimus (Torisel) coverage, effective October 11, 2025. Here's what billing teams need to know before the next claim goes out.

Aetna's updated temsirolimus coverage policy under CPB 0873 in the Aetna system defines exactly which oncology indications qualify for medical necessity approval — and which ones will get denied. The policy covers HCPCS code J9330 (temsirolimus injection, 1 mg) as the primary billable drug code, with administration billed under CPT codes 96409, 96413, 96414, 96415, 96416, and 96417. If your practice treats patients with renal cell carcinoma, mantle cell lymphoma, endometrial carcinoma, soft tissue sarcoma, or uterine sarcoma on Aetna plans, this policy directly controls your reimbursement.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Temsirolimus (Torisel) — CPB 0873
Policy Code	CPB 0873
Change Type	Modified
Effective Date	October 11, 2025
Impact Level	High
Specialties Affected	Oncology, Hematology, Gynecologic Oncology, Urology
Key Action	Audit all active temsirolimus treatment plans against the approved indication list and confirm J9330 is coded with a covered ICD-10 before submitting

---

Aetna Temsirolimus Coverage Criteria and Medical Necessity Requirements 2025

Aetna considers temsirolimus (Torisel or generic temsirolimus) medically necessary for a specific, closed list of indications. This is not a broad-use policy. Every claim must map to one of the covered diagnoses — or it will be denied.

Here are the five approved categories under this coverage policy:

1. Advanced Renal Cell Carcinoma
Temsirolimus is covered for treatment of advanced renal cell carcinoma. The policy does not restrict to a specific line of therapy for this indication. Pair J9330 with ICD-10 codes C64.1–C65.9.

2. Endometrial Carcinoma
Aetna covers temsirolimus as a single agent for subsequent-line treatment of locally advanced, recurrent, or metastatic endometrial carcinoma. "Subsequent treatment" is doing real work here — this is not a first-line indication. ICD-10 C54.1 applies for endometrial carcinoma specifically.

3. Soft Tissue Sarcoma — Two Distinct Paths
This is the most complex part of the policy. Aetna covers two different soft tissue sarcoma scenarios, and the billing setup differs between them.

#	Covered Indication Copy
1	Single-agent therapy for locally advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa), recurrent angiomyolipoma, or recurrent lymphangioleiomyomatosis. Bill J9330 alone.
2	Combination therapy for non-pleomorphic rhabdomyosarcoma, temsirolimus combined with cyclophosphamide and vinorelbine. You'll bill J9330 alongside cyclophosphamide (J9073, J9074, J9075, or J9076 depending on manufacturer) and vinorelbine (J9390). Your ICD-10 codes in the C49.x range cover soft tissue sarcoma sites.

If you're billing the combination regimen, your charge capture needs all three drug codes, plus the appropriate administration codes under CPT 96413–96417 for the infusion components.

4. Relapsed or Refractory Mantle Cell Lymphoma
Temsirolimus is covered for relapsed or refractory mantle cell lymphoma. ICD-10 codes C83.10 through C83.19 apply for mantle cell lymphoma by nodal region. Confirm the patient has prior treatment documented — "relapsed or refractory" requires medical record support.

5. Advanced or Recurrent Uterine Sarcoma (PEComa)
Aetna covers temsirolimus as a single agent for subsequent treatment of advanced, recurrent/metastatic, or inoperable PEComa of uterine origin. This is distinct from the soft tissue sarcoma PEComa indication above — it's uterine-specific and uses ICD-10 codes in the C53–C55 range.

Continuation of Therapy

Aetna's continuation criteria are straightforward. Once a patient qualifies under an approved indication, Aetna will continue to cover temsirolimus as long as there's no unacceptable toxicity and no disease progression. Document both of these at each renewal. A claim denial at the continuation stage usually means the supporting documentation didn't address one of those two conditions.

---

Aetna Temsirolimus Exclusions and Non-Covered Indications

Aetna's position is direct: all indications not listed in the approved section are considered experimental, investigational, or unproven.

The ICD-10 code table attached to this policy includes diagnosis codes for conditions like hepatoblastoma (C22.2), pancreatic malignancies (C25.x), salivary gland tumors (C07, C08.x), oropharyngeal cancers (C10.x, C11.x), retinal malignancies (C69.20–C69.22), and thyroid cancer (C73). These appear in the policy's broader code set but are not listed as covered indications.

The real issue here is this: the presence of a diagnosis code in the policy's ICD-10 table does not mean Aetna covers temsirolimus for that diagnosis. Those codes appear in the policy's reference data, but they don't map to an approved indication. Submit a claim pairing J9330 with C73 (thyroid cancer) and you're looking at a denial.

If your oncologist is using temsirolimus off-label for one of these diagnoses, talk to your compliance officer before billing. The medical necessity standard under this coverage policy is explicit, and off-label use without supporting clinical evidence will not meet it.

---

Coverage Indications at a Glance

---

Aetna Temsirolimus Billing Guidelines and Action Items 2025

The effective date for this modified policy is October 11, 2025. Claims submitted on or after that date are subject to the updated criteria. Here's what your billing team should do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Temsirolimus Under CPB 0873

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9330	HCPCS	Injection, temsirolimus, 1 mg (Torisel)

Other HCPCS Codes Related to CPB 0873

These codes apply to the cyclophosphamide + vinorelbine combination regimen for rhabdomyosarcoma.

CPT Administration Codes

Key ICD-10-CM Diagnosis Codes

Note: C07, C08.x, C10.x, C11.x, C22.2, C25.x, C69.20–C69.22, and C73 appear in the policy's ICD-10 reference data but do not correspond to covered indications under CPB 0873. Billing J9330 against these codes will result in a claim denial under Aetna's medical necessity criteria.

---